UnitedHealth Agrees to Sell Banmedica to Patria Investments for $1 Billion

UnitedHealth Group agreed to sell Banmedica, its last operating unit in South America, to Brazilian private equity firm Patria Investments for approximately $1 billion, according to sources who spoke to Reuters on November 30. Banmedica, which operates in Colombia and Chile, serves roughly 1.7 million members and will pass from a major U.S. insurer to a regional investor as the transaction moves toward a formal announcement.

The sale marks the end of a multi year withdrawal by UnitedHealth from Latin America and completes a strategic pivot away from international markets that had become costly to the company. UnitedHealth’s management has been refocusing on core U.S. businesses following heavy write downs tied to prior regional exits, a process that included earlier sales and accounting adjustments as the company reassessed its global footprint.

For patients and providers in Colombia and Chile, the change in ownership is likely to bring a period of uncertainty as Patria integrates Banmedica into its portfolio. Banmedica is a significant regional player, and its transfer could alter competitive dynamics in both countries, affecting network negotiations, provider contracts and long term investment in services. Regulators and market participants will be closely watching how the new owner balances profitability with continuity of care.

For Patria Investments, the purchase represents a substantial bet on the health sector in Latin America. As a Brazilian private equity firm, Patria has the local expertise and capital to pursue expansion or restructuring to improve margins. Private equity ownership often brings operational changes aimed at cost control and efficiency, which can accelerate innovation and investment in some cases, while also prompting concerns among labor groups, patient advocates and public officials about access and price pressures.

Financially, the sale will allow UnitedHealth to redeploy capital back into its U.S. operations, where it faces intense regulatory scrutiny, rising medical costs and continued competition in insurance and care delivery. The divestiture reduces the company’s international exposure and simplifies its corporate structure, outcomes investors often reward when management signals a clear strategic focus.

The deal was reported by sources and a formal announcement was expected following the signing. Details on regulatory approvals, exact sale proceeds and the timetable for closing were not disclosed in the initial reports. Authorities in Colombia and Chile may review the transaction for competition and consumer protection implications, as is customary in deals that involve major health care assets.

The sale underscores broader trends in the global health care industry, where large U.S. insurers are recalibrating their international strategies while regional investors step in to consolidate local markets. The coming weeks will reveal how Patria intends to run Banmedica and what the transfer of ownership will mean for patients, providers and insurers across the two countries.